再狭窄内膜增殖基因治疗  

Gene Therapy for Restenosis of Intimal Proliferation

作　　者：张新平 庞月华 冯义伯[2] 

机构地区：[1]新疆乌鲁木齐市友谊医院心内科,新疆乌鲁木齐830049 [2]华中科技大学同济医学院附属协和医院心内科,湖北武汉430022

出　　处：《心血管病学进展》2005年第4期446-449,共4页Advances in Cardiovascular Diseases

摘　　要：内膜增殖是经皮冠状动脉介入治疗后再狭窄的主要原因,包括中膜血管平滑肌细胞表型转化、增殖、迁移至内膜并合成大量的细胞外基质。内膜增殖基因治疗为预防再狭窄开创了一个崭新的途径。现就这一方面的研究结果作一综述。Intimal proliferation is a leading cause of restenosis after percutaneous coronary intervention.Phenotypical modulation,proliferation,migration of vascular smooth muscle cell from the media to the intima bordering the lumen and formation of extracellular matrix are involved in the process of intimal proliferation.Gene therapy of intimal proliferation is a most promising new tactic for preventing restenosis following percutaneous coronary intervention.This paper will review study results in this field.

关 键 词：经皮冠状动脉介入治疗 内膜增殖 再狭窄 基因治疗 

分 类 号：R543[医药卫生—心血管疾病]